The effect of co-administration of the NMDA blocker with agonist and antagonist of CB1-receptor on penicillin-induced epileptiform activity in rats

Epilepsy Research

Volumn 93, Issue 2-3, 2011, Pages 128-137

  Cakil, Duygu ^a   Yildirim, Mehmet ^b   Ayyildiz, Mustafa ^a   Agar, Erdal ^a  

^a ONDOKUZ MAYIS UNIVERSITY   (Turkey)

^b KARADENIZ TECHNICAL UNIVERSITY   (Turkey)

Author keywords

ACEA; AM 251; Cannabinoids; Epilepsy; Memantine; NMDA; Penicillin

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; ARACHIDONYL 2 CHLOROETHYLAMINE; CALCIUM; CANNABINOID; CANNABINOID 1 RECEPTOR; CANNABINOID 1 RECEPTOR AGONIST; MEMANTINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; PENICILLIN G; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICONVULSANT ACTIVITY; ARTICLE; BRAIN ELECTROPHYSIOLOGY; CALCIUM TRANSPORT; CONTROLLED STUDY; DISEASE ACTIVITY; DOSE RESPONSE; DRUG MECHANISM; DRUG MEGADOSE; EPILEPSY; EPILEPTIC STATE; LOW DRUG DOSE; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; RAT;

ANIMALS; ARACHIDONIC ACIDS; DATA INTERPRETATION, STATISTICAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; ELECTROENCEPHALOGRAPHY; EPILEPSY; EXCITATORY AMINO ACID ANTAGONISTS; MALE; MEMANTINE; PENICILLINS; PIPERIDINES; PYRAZOLES; RATS; RATS, WISTAR; RECEPTOR, CANNABINOID, CB1; RECEPTORS, N-METHYL-D-ASPARTATE;

EID: 79251637742     PISSN: 09201211     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eplepsyres.2010.11.008     Document Type: Article

References (65)

1. Ayyildiz M., Coskun S., Yildirim M., Agar E. The effects of ascorbic acid on penicillin induced epileptiform activity in rats. Epilepsia 2007, 48:1388-1395.
2. Ameri A. The effects of cannabinoids on the brain. Prog. Neurobiol. 1999, 58(4):315-348.
3. Bahremand A., Nasrabady S.E., Shafaroodi H., Ghasemi M., Dehpour A.R. Involvement of nitrergic system in the anticonvulsant effect of the cannabinoid CB(1) agonist ACEA in the pentylenetetrazole-induced seizure in mice. Epilepsy Res. 2009, 84(2-3):110-119.
4. Bahremand A., Shafaroodi H., Ghasemi M., Nasrabady S.E., Gholizadeh S., Dehpour A.R. The cannabinoid anticonvulsant effect on pentylenetetrazole-induced seizure is potentiated by ultra-low dose naltrexone in mice. Epilepsy Res. 2008, 81(1):44-51.
5. Blair R.E., Deshpande L.S., Sombati S., Falenski K.W., Martin B.R., DeLorenzo R.J. Activation of the cannabinoid type-1 receptor mediates the anticonvulsant properties of cannabinoids in the hippocampal neuronal culture models of acquired epilepsy and status epilepticus. J. Pharmacol. Exp. Ther. 2006, 317(3):1072-1078.
6. Bormann J. Memantine is a potent blocker of N-methyl-d-aspartate (NMDA) receptor channels. Eur. J. Pharmacol. 1989, 166:591-592.
7. Bosnak M., Ayyildiz M., Yildirim M., Agar E. The role of nitric oxide in the anticonvulsant effects of pyridoxine on penicillin-induced epileptiform activity in rats. Epilepsy Res. 2007, 76:49-59.
8. Buisson B., Bertrand D. Open-channel blockers at the human alpha4beta2 neuronal nicotinic acetylcholine receptor. Mol. Pharmacol. 1998, 53:555-563.
9. Caumont A.S., Octave J.N., Hermans E. Amantadine and memantine induce the expression of the glial cell line-derived neurotrophic factor in C6 glioma cells. Neurosci. Lett. 2006, 394(3):196-201.
10. Chen H.S., Pellegrini J.W., Aggarwal S.K., Lei S.Z., Warach S., Jensen F.E., Lipton S.A. Open-channel block of N-methyl-d-aspartate (NMDA) responses by memantine: therapeutic advantage against NMDA receptor-mediated neurotoxicity. J. Neurosci. 1992, 12(11):4427-4436.
11. Choi D.W. Glutamate neurotoxicity and diseases of the nervous system. Neuron 1988, 1(8):623-634.
12. Chojnacka-Wójcik E., Tatarczyńska E., Maj J. The influence of memantine on the anticonvulsant effects of the antiepileptic drugs. Pol. J. Pharmacol. Pharm. 1983, 35(6):511-515.
13. Cinar R., Freund T.F., Katona I., Mackie K., Szucs M. Reciprocal inhibition of G-protein signaling is induced by CB(1) cannabinoid and GABA(B) receptor interactions in rat hippocampal membranes. Neurochem. Int. 2008, 52(8):1402-1409.
14. Corda M., Orlandi M., Lecca D., Carboni G., Frau V., Giorgi O. Pentylenetetrazol-induced kindling in rats: effect of GABA function inhibitors. Pharmacol. Biochem. Behav. 1991, 40:329-333.
15. Czuczwar S.J., Turski W.A., Kleinrok Z. Interactions of excitatory amino acid antagonists with conventional antiepileptic drugs. Metab. Brain Dis. 1996, 11(2):143-152.
16. Danysz W., Parsons C.G. The NMDA receptor antagonist memantine as a symptomatological and neuroprotective treatment for Alzheimer's disease: preclinical evidence. Int. J. Geriatr. Psychiatry 2003, 18(suppl. 1):S23-32.
17. Deshpande L.S., Sombati S., Blair R.E., Carter D.S., Martin B.R., DeLorenzo R.J. Cannabinoid CB1 receptor antagonists cause status epilepticus-like activity in the hippocampal neuronal culture model of acquired epilepsy. Neurosci. Lett. 2007, 411(1):11-16.
18. Deshpande S.S., Smith C.D., Filbert M.G. Assessment of primary neuronal culture as a model for soman-induced neurotoxicity and effectiveness of memantine as a neuroprotective drug. Arch Toxicol. 1995, 69(6):384-390.
19. Dingledine R., McBain C.J., McNamara J.O. Excitatory amino acid receptors in epilepsy. Trends Pharmacol. Sci. 1990, 11(8):334-338.
20. Falenski K.W., Blair R.E., Sim-Selley L.J., Martin B.R., DeLorenzo R.J. Status epilepticus causes a long-lasting redistribution of hippocampal cannabinoid type 1 receptor expression and function in the rat pilocarpine model of acquired epilepsy. Neuroscience 2007, 146(3):1232-1244.
21. Falenski K.W., Carter D.S., Harrison A.J., Martin B.R., Blair R.E., DeLorenzo R.J. Temporal characterization of changes in hippocampal cannabinoid CB(1) receptor expression following pilocarpine-induced status epilepticus. Brain Res. 2009, 1262:64-72.
22. Fisher R.S. Animal models of the epilepsies. Brain Res. 1989, 14:245-278.
23. Freund T.F., Katona I., Piomelli D. Role of endogenous cannabinoids in synaptic signaling. Physiol. Rev. 2003, 83:1017-1066.
24. Gholizadeh S., Shafaroodi H., Ghasemi M., Bahremand A., Sharifzadeh M., Dehpour A.R. Ultra-low dose cannabinoid antagonist AM251 exchanges cannabinoid anticonvulsant effects in the pentylenetetrazole-induced seizure in mice. Neuropharmacology 2007, 53:763-770.
25. Gmiro V.E., Serdyuk S.E. Combined blockade of AMPA and NMDA receptors in the brain of rats prevents pentylenetetrazole-induced clonic and tonic-clonic seizures without ataxia. Bull. Exp. Biol. Med. 2008, 145(6):728-730.
26. Gutnick M.J., Connors B.W., Prince D.A. Mechanisms of neocortical epileptogenesis in vitro. J. Neurophysiol. 1982, 48(6):1321-1335.
27. Hampson A.J., Bornheim L.M., Scanziani M., Yost C.S., Gray A.T., Hansen B.M., Leonoudakis D.J., Bickler P.E. Dual effects of anandamide on NMDA receptor-mediated responses and neurotransmission. J. Neurochem. 1998, 70(2):671-676.
28. Hoffman A.F., Lupica C.R. Mechanisms of cannabinoid inhibition of GABA(A) synaptic transmission in the hippocampus. J. Neurosci. 2000, 20:2470-2479.
29. Holmes O., Wallace M.N., Campbell A.M. Comparison of penicillin epileptogenesis in rat somatosensory and motor cortex. Q J. Exp. Physiol. 1987, 72:439-452.
30. Howlett A.C., Barth F., Bonner T.I., Cabral G., Casellas P., Devane W.A., Felder C.C., Herkenham M., Mackie K., Martin B.R., Mechoulam R., Pertwee R.G. International union of pharmacology. XXVII. classification of cannabinoid receptors. Pharmacol. Rev. 2002, 54(2):161-202.
31. Howlett A.C., Breivogel C.S., Childers S.R., Deadwyler S.A., Hampson R.E., Porrino L.J. Cannabinoid physiology and pharmacology: 30 years of progress. Neuropharmacology 2004, 47:345-358.
32. Jantas D., Szymanska M., Budziszewska B., Lason W. An involvement of BDNF and PI3-K/Akt in the anti-apoptotic effect of memantine on staurosporine-evoked cell death in primary cortical neurons. Apoptosis 2009, 14(7):900-912.
33. Johnson J.W., Kotermanski S.E. Mechanism of action of memantine. Curr. Opin. Pharmacol. 2006, 6(1):61-67.
34. Katona I., Rancz E.A., Acsady L., Ledent C., Mackie K., Hajos N., Freund T.F. Distribution of CB1 cannabinoid receptors in the amygdala and their role in the control of GABAergic transmission. J. Neurosci. 2001, 21:9506-9518.
35. Kozan R., Ayyildiz M., Agar E. The effects of intracerebroventricular AM-251, a CB1-receptor antagonist, and ACEA, a CB1-receptor agonist, on penicillin-induced epileptiform activity in rats. Epilepsia 2009, 50(7):1760-1767.
36. Liu Q., Bhat M., Bowen W.D., Cheng J. Signaling pathways from CB1 receptor activation to inhibition of NMDA-mediated calcium influx and neurotoxicity in dorsal root ganglion neurons. J. Pharmacol. Exp. Ther. 2009, 331(3):1062-1070.
37. Löscher W. Basic aspects of epilepsy. Curr. Opin. Neurol. Neurosurg. 1993, 6(2):223-232.
38. Löscher W. Pharmacology of glutamate receptor antagonists in the kindling model of epilepsy. Prog. Neurobiol. 1998, 54(6):721-741.
39. Löscher W., Hönack D. High doses of memantine (1-amino-3,5-dimethyladamantane) induce seizures in kindled but not in non-kindled rats. Naunyn Schmiedebergs Arch. Pharmacol. 1990, 341(5):476-481.
40. Löscher W., Hönack D. Over-additive anticonvulsant effect of memantine and NBQX in kindled rats. Eur. J. Pharmacol. 1994, 259(2):R3-5.
41. Luszczki J.J., Czuczwar P., Cioczek-Czuczwar A., Czuczwar S.J. Arachidonyl-2-chloroethylamide, a highly selective cannabinoid CB1 receptor agonist enhances the anticonvulsant action of valproate in the mouse maximal electroshock-induced seizure model. Eur. J. Pharmacol. 2006, 547:65-74.
42. Lukomskaia N.Ia., Rukoiatkina N.I., Gorbunova L.V., Gmiro V.E., Magazanik L.G. Role of NMDA and AMPA glutamate receptors in the mechanism of korazol-induced convulsions in mice. Ross Fiziol Zh Im I M Sechenova 2003, 89(3):292-301.
43. Macdonald R.L., Barker J.L. Pentylenetetrazol and penicillin are selective antagonists of GABA-mediated post-synaptic inhibition in cultured mammalian neurons. Nature 1977, 267:720-721.
44. Mailleux P., Vanderhaeghen J.J. Glutamatergic regulation of cannabinoid receptor gene expression in the caudate-putamen. Eur. J. Pharmacol. 1994, 266(2):193-196.
45. Mares P., Mikulecká A. Different effects of two N-methyl-d-aspartate receptor antagonists on seizures, spontaneous behavior, and motor performance in immature rats. Epilepsy Behav. 2009, 14(1):32-39.
46. McNamara J.O. Cellular and molecular basis of epilepsy. J. Neurosci. 1994, 14(6):3413-3425.
47. Meldrum B.S. Excitatory amino acid receptors and their role in epilepsy and cerebral ischemia. Ann. NY Acad. Sci. 1995, 757:492-505.
48. Meldrum B.S., Turski L., Schwarz M., Czuczwar S.J., Sontag K.H. Anticonvulsant action of 1,3-dimethyl-5-aminoadamantane. Pharmacological studies in rodents and baboon, Papio papio. Naunyn Schmiedebergs Arch. Pharmacol. 1986, 332(1):93-97.
49. Naderi N., Ahari F.A., Shafaghi B., Najarkolaei A.H., Motamedi F. Evaluation of interactions between cannabinoid compounds and diazepam in electroshock-induced seizure model in mice. J. Neural Transm. 2008, 115:1501-1511.
50. Ong W.Y., Mackie K. A light and electron microscopic study of the CB1 cannabinoid receptor in primate brain. Neuroscience 1999, 92(4):1177-1191.
51. Parsons C.G., Danysz W., Quack G. Memantine is a clinically well tolerated N-methyl-d-aspartate (NMDA) receptor antagonist-a review of preclinical data. Neuropharmacology 1999, 38(6):735-767.
52. Parsons C.G., Stöffler A., Danysz W. Memantine: a NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system-too little activation is bad, too much is even worse. Neuropharmacology 2007, 53(6):699-723.
53. Paxinos G., Watson C. The Rat Brain in Stereotaxic Coordinates 1986, Academic Press, Sydney.
54. Purpura D.P., Penry J.K., Tower D.B., Woodbury D.M., Walter R.D. Experimental Models of Epilepsy 1972, Raven Press, New York.
55. Rizzo V., Ferraro G., Carletti F., Lonobile G., Cannizzaro C., Sardo P. Evidences of cannabinoids-induced modulation of paroxysmal events in an experimental model of partial epilepsy in the rat. Neurosci. Lett. 2009, 462(2):135-139.
56. Robbe D., Alonso G., Duchamp F., Bockaert J., Manzoni O.J. Localization and mechanisms of action of cannabinoid receptors at the glutamatergic synapses of the mouse nucleus accumbens. J. Neurosci. 2001, 21(1):109-116.
57. Rogawski M.A., Wenk G.L. The neuropharmacological basis for the use of memantine in the treatment of Alzheimer's disease. CNS Drug Rev. 2003, 9(3):275-308.
58. Shafaroodi H., Samini M., Moezi L., Homayoun H., Sadeghipour H., Tavakoli S., Hajrasouliha A.R., Dehpour A.R. The interaction of cannabinoids and opioids on pentylenetetrazole-induced seizure threshold in mice. Neuropharmacology 2004, 47:390-400.
59. Shen M., Piser T.M., Seybold V.S., Thayer S.A. Cannabinoid receptor agonists inhibit glutamatergic synaptic transmission in rat hippocampal cultures. J. Neurosci. 1996, 16(14):4322-4334.
60. Shearman E., Rossi S., Szasz B., Juranyi Z., Fallon S., Pomara N., Sershen H., Lajtha A. Changes in cerebral neurotransmitters and metabolites induced by acute donepezil and memantine administrations: a microdialysis study. Brain Res. Bull. 2006, 69(2):204-213.
61. Urbańska E., Dziki M., Czuczwar S.J., Kleinrok Z., Turski W.A. Antiparkinsonian drugs memantine and trihexyphenidyl potentiate the anticonvulsant activity of valproate against maximal electroshock-induced seizures. Neuropharmacology 1992, 31(10):1021-1026.
62. Vaughan C.W., Christie M.J. Retrograde signalling by endocannabinoids. Handb. Exp. Pharmacol. 2005, 168:367-383.
63. Wallace M.J., Blair R.E., Falenski K.W., Martin B.R., DeLorenzo R.J. The endogenous cannabinoid system regulates seizure frequency and duration in a model of temporal lobe epilepsy. J. Pharmacol. Exp. Ther. 2003, 307(1):129-137.
64. Wallace M.J., Martin B.R., DeLorenzo R.J. Evidence for a physiological role of endocannabinoids in the modulation of seizure threshold and severity. Eur. J. Pharmacol. 2002, 452(3):295-301.
65. Wallace M.J., Wiley J.L., Martin B.R., DeLorenzo R.J. Assessment of the role of CB1 receptors in cannabinoid anticonvulsant effects. Eur. J. Pharmacol. 2001, 428(1):51-57.